MaaT Pharma

📰 MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer.bsky.social) 2025.
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.

👉 Full press release: www.maatpharma.com/november-5-2...

📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025.
👉 Read the full press release: www.maatpharma.com/november-3-2...

📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!

👉 Read the full press release: www.maatpharma.com/november-4-2...

📢 Proud to see our lead candidate MaaT013 highlighted in a new review in Current Opinion in Immunology by E. Godefroy and F. Altare, exploring how the gut microbiota regulates immune responses in acute graft-versus-host disease (#aGvHD).

🔬Open-access article: www.sciencedirect.com/science/arti...

📢 Meet Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, during the Annual Meeting of the SITC in National Harbor, Maryland, USA.

🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.

Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directions Acute graft-versus-host disease (aGVHD) is a significant complication of allogeneic hematopoietic cell transplantation (allo-HCT), characterized by im…

Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (#aGvHD) in Current Opinion in Immunology.

🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology

📢 Join MaaT Pharma as an 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗜𝗻𝘁𝗲𝗿𝗻 (𝗠/𝗙)!

📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...

🎓 6-month internship – starting early 2026
📍 Saint-Quentin-Fallavier (France)

📢 Join MaaT Pharma as an R&D Project Manager (M/F)!

🎯 Do you have strong project management experience in the pharmaceutical or biotech industry and a passion for innovation in oncology and microbiome research? This opportunity is for you!

🔬 Full job description: www.maatpharma.com/wp-content/u...

📢 [#Internship] – Join MaaT Pharma as a Quality Assurance Intern (M/F)!

📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...

📅 6-month internship – starting January/February 2026
📍 Lyon (France)

📢 Join MaaT Pharma as a Biological Collection Project Manager (M/F)!

📩 Send your resume and a short motivation email to careers@maat-pharma.com to apply now!

🔬 Detailed job description: www.maatpharma.com/wp-content/u...

#ProjectManagement #Biotech #Microbiome #Production #Quality #Regulatory

📢 Noémie Laurent, Chargée des ressources humaines chez MaaT Pharma, et Michèle Boyer de Zordi, chargée de Mission RSE et HSE, seront présentes au Forum emploi des industries de santé 2025, le 9 octobre à Lyon.
👉 Contribuez à faire avancer la science du microbiote : www.forumemploi-industriessante.fr

📰 [PressRelease] - We’re proud to share that the DSMB has issued a positive recommendation following the second safety interim analysis of our Phase 2b PHOEBUS trial evaluating MaaT033 in patients receiving allo-HSCT.

👉 Read the full press release here: www.maatpharma.com/october-7-20...

Some keen Observations in Our October issue!

🦠 Cancer microbiome
🌊 Marine microbes in warming oceans
🌐 broad-range phages
🧬 genetically minimised Salmonella
🔧 Viral infection mechanisms
🧪 Oxaloacetate antiviral defence

and more, here: www.nature.com/nmicrobiol/v...

Thinking about a postdoc in microbiome science?
Our lab at the MPI for Biology (Tübingen) builds on the culture I established at Cornell: collaborative, creative, and internationally diverse. Postdocs lead their own projects with secure funding. Join us!
#PostdocJobs #HostMicrobe #AcademicJobs

📅 Frederic Fasano, Directeur Stratégie et Développement Corporate chez MaaTPharma interviendra à la conférence annuelle du Musée de sciences biologiques Docteur Mérieux : « Vivre en Intelligences avec les Microbes ».

👉Plus d’informations : www.musee-docteur-merieux.com/conference-f...

📅 Emilie Plantamura, Directrice Médicale adjointe chez MaaT Pharma, interviendra lors du symposium « Développer une médecine du microbiote pour restaurer la symbiose hôte-microbes », organisé dans le cadre des Entretiens Jacques Cartier 2025.
👉Inscrivez-vous ici : www.billetweb.fr/developper-u...

📅 Join Eric Soyer, CFO at MaaT Pharma, and Guilhaume Debroas, our Head of Investor Relations, at the Portzamparc Groupe BNP Paribas’ digital Biotech & Health Seminar 2025, on October 1, 2025.

#Biotech #Health #Investments #DigitalEvent #Investors #LifeSciences #Microbiome #Pharma #Portzamparc

YouTube video by Bloomberg Originals This Biotech Breakthrough Could Change Medicine

🩸 To close #BloodCancerAwarenessMonth, we share a patient story on life-threatening #aGvHD after transplant, featured by Bloomberg with Dr. Loschi’s insights.
🎥 Watch the full story: youtu.be/P8pd0TlITpo?...

At MaaT Pharma, we advance microbiome science to tackle unmet needs in hemato-oncology.

🎥 [Media] À l’occasion de la publication de nos résultats semestriels, notre Directeur Financier Eric Soyer est revenu sur nos derniers jalons créateurs de valeur pour Arnaud Bivès - Boursier.com.

👉 Lire l’interview complète : www.boursier.com/actions/actu...

📅 Meet Eric Soyer, Chief Financial Officer at MaaT Pharma, and Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, at KBC Securities' Life Sciences Conference on Thursday, September 25, 2025, in Brussels.

#IR #Investors #Finance #Microbiome #Innovation #Pharma #Science #Healthcare #KBC

🩸 For #BloodCancerAwarenessMonth, we spotlight the gut microbiome: a key player in immunity and cancer care. Microbiotherapies in trials aim to restore balance, boost treatment efficacy, and reduce post-transplant complications.

👉 Learn more: www.maatpharma.com/patients-car...

📢 [Euronext Indices] - MaaT Pharma (Euronext Paris: MAAT) has been included in the CAC Small, CAC Mid & Small, and CAC All-Tradable indices following the annual review of the Euronext Paris indices.

#Euronext #Indices #CAC #Innovation #Microbiome #Oncology

📄 [Press release] - MaaT Pharma Publishes its Half Year 2025 Financial Results and Provides a Business Update

👉 Read the full press release for more information: www.maatpharma.com/september-17...

#BusinessUpdate #FinancialResults #Oncology #Microbiome #aGvHD #Hematology

📅 [Event] – Join Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, at the 8th edition of the #investor Forum Lyon Pole Bourse.

📍 Palais de la Bourse – Place de la Bourse, Lyon, France
🗓 September 23, 2025

#LyonPoleBourse #LyonForum2024 #InvestInBiotech #HealthcareInvestors

📅 Proud to sponsor the 16th edition of the #SFGMTC workshops on harmonizing practices in transplantation and cell therapy!

Join Alex Kiss, our Medical Science Liaison, to discuss on innovative strategies to improve patient survival following allo-HSCT.
📍 Espace Inkermann Chatillon, Lille, France

🩸 #BloodCancerAwarenessMonth – Allo-HSCT can be life-saving, but may also cause #GvHD, a life-threatening complication. Standard treatments help many patients, yet resistance leaves unmet needs, driving research into microbiome-based therapies.

👉 Learn more here: www.maatpharma.com/patients-car...

🩸 September is #BloodCancerAwarenessMonth and we are joining the global effort to increase understanding of blood cancers.
👉 Want to learn more? Visit our dedicated page to discover information about blood cancer, bone marrow transplantation and stem cell donation: www.maatpharma.com/patients-car...

🎥 Dans une interview accordée à BFM Business, Frederic Fasano, Directeur Général Adjoint de MaaT Pharma, partage deux moments clés de ces derniers mois, et la stratégie qui guide l'entreprise.
👉 Découvrez l’échange complet avec @Erwan Morice : www.youtube.com/watch?v=XH9l...
@bfmbusiness.bsky.social

📄 [Press release] – MaaT Pharma Secures €37.5 Million Loan From European Investment Bank @eib.org Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

👉 For more information, read the full press release: www.maatpharma.com/july-28-2025...

World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings The European Medicines Agency has started reviewing for potential EU marketing approval six new products, including MaaT Pharma’s microbiota therapeutic for acute-graft-versus-host disease, and AstraZ...

📰 [Media] - MaaT Pharma featured in Citeline for advancing the potential world’s first hemato-oncology microbiota therapeutic!
Thanks to Neena Brizmohun for highlighting Xervyteg® among the latest EU filings now under EMA review.

👉 Read the full article here: insights.citeline.com/pink-sheet/p...